Mylan Inc's subsidiary Mylan Pharmaceuticals Inc. has launched Lithium Carbonate extended-release tablets USP, 300 mg and  Desloratadine tablets, 5 mg.

Lithium Carbonate extended-release tablets is the generic version of Noven Therapeutic's Lithobid tablets, which are indicated for the treatment of manic episodes of bipolar disorder and as a maintenance treatment for individuals with a diagnosis of bipolar disorder. Desloratadine tablets is the generic version of Schering-Plough's Clarinex allergy medication.

According to IMS Health, Lithium Carbonate extended-release tablets USP, 300 mg, had US sales of approximately $21 million and Desloratadine tablets, 5 mg, had US sales of approximately $194.6 million for the 12 months ending March 31, 2012.

Currently, Mylan has 167 ANDAs pending FDA approval representing $83.8 billion in annual sales, according to IMS Health. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $25.6 billion in annual brand sales, for the 12 months ending December 31, 2011, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership.